Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence

Oncogene

Volumn 32, Issue 22, 2013, Pages 2792-2798

  Tang, Y ^a   Horikawa, I ^a   Ajiro, M ^a   Robles, A I ^a   Fujita, K ^a   Mondal, A M ^a   Stauffer, J K ^b   Zheng, Z M ^a   Harris, C C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

alternative splicing; cellular senescence; isoform; p53; SRSF3

Indexed keywords

MESSENGER RNA; PROTEIN P53; PROTEIN P53BETA; RNA BINDING PROTEIN; SMALL INTERFERING RNA; SRSF3 PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CARCINOGENESIS; CELL DIVISION; CELLULAR SENESCENCE; DOWN REGULATION; EXON; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; SENESCENCE; UPREGULATION;

ALTERNATIVE SPLICING; CELL AGING; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; FIBROBLASTS; HUMANS; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA PRECURSORS; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84879418287     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.288     Document Type: Article

References (75)

1. Celotto AM, Graveley BR. Alternative splicing of the Drosophila Dscam pre-mRNA is both temporally and spatially regulated. Genetics 2001; 159: 599-608.
2. Zheng ZM. Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression. J Biomed Sci 2004; 11: 278-294.
3. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003; 302: 2141-2144.
4. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476.
5. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 2009; 11: 1135-1142.
6. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004; 61: 2189-2199.
7. Kannan K, Wang L, Wang J, Ittmann MM, Li W, Yen L. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci USA 2011; 108: 9172-9177.
8. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008; 7: 1214-1224.
9. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647-7654.
10. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16: 670-676.
11. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A et al. Con-stitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759-16765.
12. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008; 36: 6535-6547.
13. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2009; 463: 364-368.
14. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010; 24: 2343-2364.
15. Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, Sung HK et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 2011; 147: 132-146.
16. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. Regulation of alternative splicing by histone modifications. Science 2010; 327: 996-1000.
17. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009; 33: 591-601.
18. Salomonis N, Schlieve CR, Pereira L, Wahlquist C, Colas A, Zambon AC et al. Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation. Proc Natl Acad Sci USA 2010; 107: 10514-10519.
19. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-233.
20. Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res 2008; 68: 657-663.
21. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-1093.
22. He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS et al. Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 2010; 30: 356-365.
23. Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY et al. Regulation of gene expression by the RNA-binding protein Sam68 in cancer. Biochem Soc Trans 2008; 36(Pt 3): 505-507.
24. Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, Lopez-Picazo JM, Torre W et al. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 2010; 16: 4113-4125.
25. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185-193.
26. Karni R, Hippo Y, Lowe SW, Krainer AR. The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci USA 2008; 105: 15323-15327.
27. Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res 2010; 70: 3975-3984.
28. Jia R, Li C, McCoy JP, Deng CX, Zheng ZM. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int J Biol Sci 2010; 6: 806-826.
29. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-636.
30. Franza Jr BR, Maruyama K, Garrels JI, Ruley HE. In vitro establishment is not a sufficient prerequisite for transformation by activated ras oncogenes. Cell 1986; 44: 409-418.
31. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibro-blasts requires at least two cooperating oncogenes. Nature 1983; 304: 596-602.
32. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
33. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al. Onco-gene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444: 638-642.
34. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637.
35. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-740.
36. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. Curr Opin Cell Biol 2008; 20: 150-155.
37. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-730.
38. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 2004; 14: 501-513.
39. Wynford-Thomas D. p53: guardian of cellular senescence. J Pathol 1996; 180: 118-121.
40. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005 19: 2122-2137.
41. Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K. Expression of novel p53 isoforms in oral lichen planus. Oral Oncol 2008; 44: 156-161.
42. Garcia-Alai MM, Tidow H, Natan E, Townsley FM, Veprintsev DB, Fersht AR. The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site. Protein Sci 2008; 17: 1671-1678.
43. Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res 2006; 34: 5603-5612.
44. Rohaly G, Chemnitz J, Dehde S, Nunez AM, Heukeshoven J, Deppert W et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005; 122: 21-32.
45. Khoury MP, Bourdon JC. p53 Isoforms: an intracellular microprocessor? Genes Cancer 2011; 2: 453-465.
46. Jumaa H, Guenet JL, Nielsen PJ. Regulated expression and RNA processing of transcripts from the Srp20 splicing factor gene during the cell cycle. Mol Cell Biol 1997; 17: 3116-3124.
47. Shaw SD, Chakrabarti S, Ghosh G, Krainer AR. Deletion of the N-terminus of SF2/ASF permits RS-domain-independent pre-mRNA splicing. PLoS One 2007; 2: e854.
48. Shen H, Green MR. RS domains contact splicing signals and promote splicing by a common mechanism in yeast through humans. Genes Dev 2006; 20: 1755-1765.
49. Zahler AM, Lane WS, Stolk JA, Roth MB. SR proteins: a conserved family of pre-mRNA splicing factors. Genes Dev 1992; 6: 837-847.
50. Zhu J, Krainer AR. Pre-mRNA splicing in the absence of an SR protein RS domain. Genes Dev 2000; 14: 3166-3178.
51. Anko ML, Morales L, Henry I, Beyer A, Neugebauer KM. Global analysis reveals SRp20-and SRp75-specific mRNPs in cycling and neural cells. Nat Struct Mol Biol 2010; 17: 962-970.
52. Chen W, Itoyama T, Chaganti RS. Splicing factor SRP20 is a novel partner of BCL6 in a t(3;6)(q27;p21) translocation in transformed follicular lymphoma. Genes Chromosomes Cancer 2001; 32: 281-284.
53. Huang Y, Steitz JA. Splicing factors SRp20 and 9G8 promote the nucleocyto-plasmic export of mRNA. Mol Cell 2001; 7: 899-905.
54. Jumaa H, Nielsen PJ. The splicing factor SRp20 modifies splicing of its own mRNA and ASF/SF2 antagonizes this regulation. Embo J 1997; 16: 5077-5085.
55. Sen S, Talukdar I, Webster NJ. SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Mol Cell Biol 2009; 29: 871-880.
56. He X, Ee PL, Coon JS, Beck WT. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res 2004; 10: 4652-4660.
57. Fujita K, Horikawa I, Mondal AM, Jenkins LM, Appella E, Vojtesek B et al. Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol 2010; 12: 1205-1212.
58. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. Embo J 2003; 22: 4212-4222.
59. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998; 12: 3008-3019.
60. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113: 703-716.
61. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-346.
62. Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T et al. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol 2000; 20: 2803-2808.
63. Aubol BE, Adams JA. Applying the Brakes to Multisite SR Protein Phosphorylation: Substrate-Induced Effects on the Splicing Kinase SRPK1. Biochemistry 2011; 50: 6888-6900.
64. Jiang K, Patel NA, Watson JE, Apostolatos H, Kleiman E, Hanson O et al. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phos-phorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid. Endocrinology 2009; 150: 2087-2097.
65. Kanj SS, Dandashi N, El-Hed A, Harik H, Maalouf M, Kozhaya L et al. Ceramide regulates SR protein phosphorylation during adenoviral infection. Virology 2006; 345: 280-289.
66. Misteli T, Caceres JF, Clement JQ, Krainer AR, Wilkinson MF, Spector DL. Serine phosphorylation of SR proteins is required for their recruitment to sites of transcription in vivo. J Cell Biol 1998; 143: 297-307.
67. Sanford JR, Bruzik JP. Developmental regulation of SR protein phosphorylation and activity. Genes Dev 1999; 13: 1513-1518.
68. Sciabica KS, Dai QJ, Sandri-Goldin RM. ICP27 interacts with SRPK1 to mediate HSV splicing inhibition by altering SR protein phosphorylation. Embo J 2003; 22: 1608-1619.
69. Tacke R, Chen Y, Manley JL. Sequence-specific RNA binding by an SR protein requires RS domain phosphorylation: creation of an SRp40-specific splicing enhancer. Proc Natl Acad Sci USA 1997; 94: 1148-1153.
70. Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD. Regulation of SR protein phos-phorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes Dev 2009; 23: 482-495.
71. Kang JG, Pripuzova N, Majerciak V, Kruhlak M, Le SY, Zheng ZM. Kaposi's sarcoma-associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression. J Virol 2011; 85: 2620-2630.
72. Majerciak V, Yamanegi K, Nie SH, Zheng ZM. Structural and functional analyses of Kaposi sarcoma-associated herpesvirus ORF57 nuclear localization signals in living cells. J Biol Chem 2006; 281: 28365-28378.
73. Lanigan F, Geraghty JG, Bracken AP. Transcriptional regulation of cellular senescence. Oncogene 2011; 30: 2901-2911.
74. Lazzerini Denchi E, Attwooll C, Pasini D, Helin K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005; 25: 2660-2672.
75. Jia R, Liu X, Tao M, Kruhlak M, Guo M, Meyers C et al. Control of the papillomavirus early-to-late switch by differentially expressed SRp20. J Virol 2009; 83: 167-180.